189 related articles for article (PubMed ID: 32199549)
41. A retrospective, observational study on medication for opioid use disorder during pregnancy and risk for neonatal abstinence syndrome.
Sujan A; Cleary E; Douglas E; Aujla R; Boyars L; Smith C; Guille C
Fam Pract; 2022 Mar; 39(2):311-315. PubMed ID: 34537839
[TBL] [Abstract][Full Text] [Related]
42. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
[TBL] [Abstract][Full Text] [Related]
43. OUD MEETS: A novel program to increase initiation of medications for opioid use disorder and improve outcomes for hospitalized patients being discharged to skilled nursing facilities.
Tassey TE; Ott GE; Alvanzo AAH; Peirce JM; Antoine D; Buresh ME
J Subst Abuse Treat; 2022 Dec; 143():108895. PubMed ID: 36215913
[TBL] [Abstract][Full Text] [Related]
44. Implementation of a pharmacist care manager model to expand availability of medications for opioid use disorder.
DeRonne BM; Wong KR; Schultz E; Jones E; Krebs EE
Am J Health Syst Pharm; 2021 Feb; 78(4):354-359. PubMed ID: 33326564
[TBL] [Abstract][Full Text] [Related]
45. Utilization of treatment by Medicaid enrollees with opioid use disorder and co-occurring substance use disorders.
O'Brien P; Henke RM; Schaefer MB; Lin J; Creedon TB
Drug Alcohol Depend; 2020 Dec; 217():108261. PubMed ID: 32979735
[TBL] [Abstract][Full Text] [Related]
46. Association between clinically recognized suicidality and subsequent initiation or continuation of medications for opioid use disorder.
Frost MC; Richards JE; Blosnich JR; Hawkins EJ; Tsui JI; Edelman EJ; Williams EC
Drug Alcohol Depend; 2022 Aug; 237():109521. PubMed ID: 35716644
[TBL] [Abstract][Full Text] [Related]
47. A Comparison of Medication for Opioid Use Disorder Treatment Strategies for Persons Who Inject Drugs With Invasive Bacterial and Fungal Infections.
Marks LR; Munigala S; Warren DK; Liss DB; Liang SY; Schwarz ES; Durkin MJ
J Infect Dis; 2020 Sep; 222(Suppl 5):S513-S520. PubMed ID: 32877547
[TBL] [Abstract][Full Text] [Related]
48. Mortality in Treatment-seeking Older Adults Receiving Medications for Opioid Use Disorder.
Weber AN; Arndt S; Miskle B; Bormann NL
J Addict Med; 2024 Mar-Apr 01; 18(2):185-187. PubMed ID: 38084854
[TBL] [Abstract][Full Text] [Related]
49. Treatment utilization among persons with opioid use disorder in the United States.
Wu LT; Zhu H; Swartz MS
Drug Alcohol Depend; 2016 Dec; 169():117-127. PubMed ID: 27810654
[TBL] [Abstract][Full Text] [Related]
50. Opioid Use Disorder Stigma, Discrimination, and Policy Attitudes in a National Sample of U.S. Young Adults.
Adams ZW; Taylor BG; Flanagan E; Kwon E; Johnson-Kwochka AV; Elkington KS; Becan JE; Aalsma MC
J Adolesc Health; 2021 Aug; 69(2):321-328. PubMed ID: 33579622
[TBL] [Abstract][Full Text] [Related]
51. Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.
Hughto JMW; Tapper A; Rapisarda SS; Stopka TJ; Palacios WR; Case P; Silcox J; Moyo P; Green TC
Subst Abuse Treat Prev Policy; 2023 May; 18(1):30. PubMed ID: 37217975
[TBL] [Abstract][Full Text] [Related]
52. How a Medication for Opioid Use Disorder Curriculum Translates into Experiences and Internal Medicine Residents' Understanding of Patients with Opioid Use Disorder.
Robles M; Mortazavi L; Vannerson J; Matthias MS
Teach Learn Med; 2022; 34(5):514-521. PubMed ID: 33974460
[TBL] [Abstract][Full Text] [Related]
53. Developing a cascade of care for opioid use disorder among individuals in jail.
Ray B; Victor G; Cason R; Hamameh N; Kubiak S; Zettner C; Dunnigan M; Comartin E; Costello M
J Subst Abuse Treat; 2022 Jul; 138():108751. PubMed ID: 35241352
[TBL] [Abstract][Full Text] [Related]
54. Defining a recovery-oriented cascade of care for opioid use disorder: A community-driven, statewide cross-sectional assessment.
Yedinak JL; Goedel WC; Paull K; Lebeau R; Krieger MS; Thompson C; Buchanan AL; Coderre T; Boss R; Rich JD; Marshall BDL
PLoS Med; 2019 Nov; 16(11):e1002963. PubMed ID: 31743335
[TBL] [Abstract][Full Text] [Related]
55. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
[TBL] [Abstract][Full Text] [Related]
56. The intersection of race and opioid use disorder treatment: A quantitative analysis.
Entress RM
J Subst Abuse Treat; 2021 Dec; 131():108589. PubMed ID: 34426022
[TBL] [Abstract][Full Text] [Related]
57. The effect of medications for opioid use disorder (MOUD) on residential treatment completion and retention in the US.
Stahler GJ; Mennis J
Drug Alcohol Depend; 2020 Jul; 212():108067. PubMed ID: 32445926
[TBL] [Abstract][Full Text] [Related]
58. Disparities in receipt of medications for opioid use disorder among pregnant women.
Henkhaus LE; Buntin MB; Henderson SC; Lai P; Patrick SW
Subst Abus; 2022; 43(1):508-513. PubMed ID: 34270396
[No Abstract] [Full Text] [Related]
59. Addressing opioid use disorder among rural pregnant and postpartum women: a study protocol.
Bryan MA; Smid MC; Cheng M; Fortenberry KT; Kenney A; Muniyappa B; Pendergrass D; Gordon AJ; Cochran G
Addict Sci Clin Pract; 2020 Oct; 15(1):33. PubMed ID: 33129355
[TBL] [Abstract][Full Text] [Related]
60. Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders.
Saunders EC; Moore SK; Walsh O; Metcalf SA; Budney AJ; Scherer E; Marsch LA
J Subst Abuse Treat; 2020 Apr; 111():54-66. PubMed ID: 32076361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
